Open Access
Review
Table 1
- Current regimen of treatment for lung cancer.
| Drug name | Generic name | Use | ||
| Xeloda | Capecitabine | anti-metabolites | ||
| Avastin | Bevacizumab | VEGF/VEGFR inhibitors | ||
| Tarceva | Erlotinib | EGFR inhibitors | ||
| Cytoxan | Cyclophosphamide | alkylating agents | ||
| Taxol | Paclitaxel | mitotic inhibitorsa | ||
| Taxotere | Docetaxel | mitotic inhibitors | ||
| Gemzar | Gemcitabine | antimetabolites | ||
| Erbitux | Cetuximab | EGFR inhibitors | ||
| Alimta | Pemetrexed | antimetabolites | ||
| Navelbine | Vinorelbine | mitotic inhibitors | ||
| Platinol | Cisplatin | alkylating agents | ||
| Trexall | Methotrexate | antimetabolites, antipsoriatics, antirheumatics | ||
| Ethyol | Amifostine | antineoplastic detoxifying agents | ||
| Iressa | Gefitinib | EGFR inhibitor | ||
| Neosar | Cyclophosphamide | alkylating agents | ||
| Platinol-AQ | Cisplatin | alkylating agents | ||
| Photofrin | Porfimer | miscellaneous antineoplastics | ||
| Onxol | Paclitaxel | mitotic inhibitors |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.